Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53-DC Vaccine and T-cell Therapy in SCLC
NCT00776295Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- May 2007
- Primary completion
- Jun 2010
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Ad.p53-DC vaccine in small cell lung cancer (SCLC), sponsored by Moffitt Cancer Center. Primary endpoint: 1-year Overall Survival. Started May 2007; status: terminated.
02
Drugs
Ad.p53-DC vaccine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00776295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00776295.